Industry Outlook
The stem cell alopecia treatment market is set to grow at a compounded annual growth rate (CAGR) of 5.1% during the forecast period from 2018 to 2026. According to the research findings of National Institute of Health (NIH), the global prevalence rate of androgenic alopecia is 15.33% and is highly variable according to geographical region. It is highly prevalent in the Caucasian population which is reported to be a genetic anomaly. Currently the U.S.F.D.A. has approved only 2 drugs for treating alopecia which are Minoxidil and Finasteride, which have shown excellent therapeutic efficacy but is associated with severe adverse events. There is tremendous scope for stem cell technology to create regenerative medicine to address androgenic alopecia by employing human adipose tissue and umbilical cord embryonic mesenchymal stem cells.
Market Synopsis
Get a sample copy for more information
"Increasing deregulation of KRT37 by androgens due to hormonal and nutritional imbalance drive the male pattern baldness market growth"
Male pattern baldness is reigning the indication segment for stem cell alopecia treatment market. It is the most common type of hair loss in men throughout the globe affecting 80% of the Caucasian population. As per the research citing of U.S. National Library of Medicine (NLM), more than 50% of men above the age of 50 years suffer from hair loss to some extent. The main causative agents are increasing deregulation of KRT37 by androgens owing to hormonal and nutritional imbalance in men. Female pattern baldness has garnered tremendous attention in the last decade on account of increasing socio-economic burden, depression & anxiety in women suffering with alopecia and rising technological advancement in dermatology science to address female pattern baldness issue. It has been reported to occur in women after menopause, hormonal imbalance is associated with the hair loss.
Get a sample copy for more information
"Rising prevalence of androgenic alopecia and significant rise in specialty clinics & research institute treating alopecia drive the market growth in North America"
North America is dominating the regional segment for stem cell alopecia treatment market with a share of 35%. The major factors propelling the market growth in North America region are rising prevalence of androgenic alopecia and significant rise in specialty clinics and research institute indulged in stem cell alopecia treatment. Existence of technologically advanced dermatology segment and high disposable income further support the market growth in North America region. Europe is the second largest market accountable for 30% share owing to the increasing number of patients suffering with hair loss due to chemotherapy and radiation therapy. Strategic collaboration of academic research institute and pharmaceutical companies will provide necessary impetus to the research and development segment specializing in stem cell alopecia treatment. Asia Pacific represents 20% market share and is set to register impressive growth in the near future on account of rising prevalence of female pattern baldness and rise in per capita income.
Get a sample copy for more information
Historical & Forecast Period
This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.
Report Scope by Segments
The market is segmented by indication and by geography.
| ATTRIBUTE |
DETAILS |
| Research Period |
2017-2027 |
| Base Year |
2018 |
| Forecast Period |
2019-2027 |
| Historical Year |
2017 |
| Unit |
USD Million |
| Segmentation |
By Indication (2016–2026; US$ Mn)
• Male Pattern Baldness
• Female Pattern Baldness
• Others
|
|
Geography Segment (2016–2026; US$ Mn)
• North America (U.S., Canada)
• Europe (U.K., Germany, Rest of Europe)
• Asia Pacific (China, Japan, Rest of APAC)
• Latin America (Brazil, Mexico, Rest of Latin America)
• Middle East and Africa (GCC, Rest of Middle East and Africa)
|
Biopharmaceutical companies highly indulged in stem cell alopecia treatment market are APEX Biologix, Belgravia Center, Kerastem, Riken Research Institute, RepliCel, Sanford Burnham Prebys Medical Discovery Institute and University of Southern California.
Key questions answered in this report
- Which research institutes are developing stem cell technology to address androgenic alopecia problems?
- What is KRT37 and how is it related to androgenic alopecia?
- What is the global prevalence rate of alopecia and its ethnic variability?
- Which stem cells are being currently employed to develop regenerative medicine to treat alopecia?
- What is the disease etiology of male and female pattern baldness?
- What will be the market performance of Asia Pacific region in the near future?
